These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 22879389

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 4. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [Abstract] [Full Text] [Related]

  • 5. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM.
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
    Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP.
    Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
    [Abstract] [Full Text] [Related]

  • 9. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
    Neuroendocrinology; 2012 Aug 16; 96(3):228-37. PubMed ID: 22378048
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 16; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 14. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 16; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 15. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 16; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 16. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A.
    Exp Hematol; 2008 Apr 16; 36(4):443-50. PubMed ID: 18343280
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.
    Clin Cancer Res; 2006 Sep 01; 12(17):5165-73. PubMed ID: 16951235
    [Abstract] [Full Text] [Related]

  • 19. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.
    Int J Cancer; 2018 Jan 01; 142(1):202-213. PubMed ID: 28905990
    [Abstract] [Full Text] [Related]

  • 20. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T.
    Bull Cancer; 2011 Dec 01; 98(12):1431-7. PubMed ID: 22133994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.